Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Voltage-dependent T-type calcium channel subunit alpha-1H (CaV3.2) is a low-voltage-activated (LVA) ion channel that plays a critical role in regulating cellular excitability and rhythmic firing patterns (UniProt, 2024; Wikipedia, 2024). Unlike high-voltage-activated channels, CaV3.2 opens at membrane potentials near the resting state, allowing for the influx of calcium ions that trigger burst firing in neurons and pacemaker activity in the heart (NIH, 2022; ResearchGate, 2026). It is widely expressed in the central and peripheral nervous systems, as well as in cardiac and endocrine tissues, where it contributes to processes such as neurotransmitter release, hormone secretion, and sensory perception (Open Microbiology Journal, 2018; Neuroscience, 2019). Dysregulation or genetic mutations in the CACNA1H gene, which encodes this subunit, are strongly associated with various pathologies, including childhood absence epilepsy, chronic and neuropathic pain, and primary aldosteronism (NIH, 2024; ResearchGate, 2026). In the heart, CaV3.2 is involved in the pacemaker activity of the sinoatrial node, making it a potential target for managing certain arrhythmias (YouTube, 2015). In the sensory system, it is a key mediator of pain signaling in the dorsal root ganglia, and its inhibition is a major strategy for developing novel analgesics (Guide to Pharmacology, 2024; NIH, 2024). Pharmacological agents such as ethosuximide and zonisamide exert their effects partly through the inhibition of T-type channels, while newer, more selective blockers like Z944 and ACT-709478 are being investigated for their potential to treat pain and epilepsy with fewer side effects (NIH, 2024; Guide to Pharmacology, 2024). Additionally, CaV3.2 has been implicated in neurodevelopmental disorders like autism and neurodegenerative conditions such as amyotrophic lateral sclerosis (ResearchGate, 2026; NIH, 2024).
Inhibition of low-voltage-activated T-type calcium channels
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-dependent T-type calcium channel subunit alpha-1H (CaV3.2) (CaV3.2).